DNA repair is essential for routine monitoring and repair of damage imparted to our genetic material by exposure to endogenous and exogenous carcinogens, including reactive oxygen species, UV light, and chemicals such as those found in cigarette smoke. Without DNA repair pathways, the continual assault on our DNA would be highly mutagenic and the risk of cancer increased. Paradoxically, the same pathways that help prevent cancer development are detrimental to the efficacy of DNA-damaging cancer therapeutics such as cisplatin. Recent studies demonstrate the inverse relationship between DNA repair capacity and efficacy of platinum-based chemotherapeutics: increased DNA repair capacity leads to resistance, while decreased capacity leads to increased sensitivities. Cisplatin's cytotoxic effects are mediated by formation of intrastrand DNA crosslinks, which are predominantly repaired via the nucleotide excision repair (NER) pathway. In an effort to personalize the treatment of cancers based on DNA repair capacity, we developed an ELISA-based assay to measure NER activity accurately and reproducibly as a prognostic for platinum-based treatments. Here we present an overview of DNA repair and its link to cancer and therapeutics. We also present data demonstrating the ability to detect the proteins of the pre-incision complex within the NER pathway from cell and tissue extracts. Antioxid. Redox Signal. 14, 2465–2477.
Get full access to this article
View all access options for this article.
References
1.
Al–TassanN, ChmielNH, MaynardJ, FlemingN, LivingstonAL, WilliamsGT, HodgesAK, DaviesDR, DavidSS, SampsonJR, CheadleJP. Inherited variants of MYH associated with somatic G:C–>T:A mutations in colorectal tumors. Nat Genet, 30:227–232. 2002.
2.
AlbertsB. Redefining cancer research. Science, 325:1319. 2009.
3.
AraujoSJ, NiggEA, WoodRD. Strong functional interactions of TFIIH with XPC and XPG in human DNA nucleotide excision repair, without a preassembled repairosome. Mol Cell Biol, 21:2281–2291. 2001.
4.
AraujoSJ, TirodeF, CoinF, PospiechH, SyvaojaJE, StuckiM, HubscherU, EglyJM, WoodRD. Nucleotide excision repair of DNA with recombinant human proteins: definition of the minimal set of factors, active forms of TFIIH, and modulation by CAK. Genes Devel, 14:349–359. 2000.
5.
BattyDP, WoodRD. Damage recognition in nucleotide excision repair of DNA. Gene, 241:193–204. 2000.
BeskowC, SkikunieneJ, HolgerssonA, NilssonB, LewensohnR, KanterL, ViktorssonK. Radioresistant cervical cancer shows upregulation of the NHEJ proteins DNA-PKcs, Ku70 and Ku86. Br J Cancer, 101:816–821. 2009.
8.
BiswasEE, ZhuFX, BiswasSB. Stimulation of RTH1 nuclease of the yeast Saccharomyces cerevisiae by replication protein A. Biochemistry, 36:5955–5962. 1997.
9.
BradburyPA, KulkeMH, HeistRS, ZhouW, MaC, XuW, MarshallAL, ZhaiR, HooshmandSM, AsomaningK, SuL, ShepherdFA, LynchTJ, WainJC, ChristianiDC, LiuG. Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes. Pharmacogenet Genomics, 19:613–625. 2009.
10.
CamenischU, DipR, SchumacherSB, SchulerB, NaegeliH. Recognition of helical kinks by xeroderma pigmentosum group A protein triggers DNA excision repair. Nat Struct Mol Biol, 13:278–284. 2006.
11.
CleaverJ. Defective repair replication of DNA in xeroderma pigmentosum. Nature, 218:652–656. 1968.
12.
CoinF, OksenychV, EglyJM. Distinct roles for the XPB/p52 and XPD/p44 subcomplexes of TFIIH in damaged DNA opening during nucleotide excision repair. Mol Cell, 26:245–256. 2007.
13.
CulottaE, KoshlandDE. Molecule of the Year—DNA repair works its way to the top. Science, 266:1926–1929. 1994.
14.
DunbarSA. Applications of Luminex xMAP technology for rapid, high-throughput multiplexed nucleic acid detection. Clin Chim Acta, 363:71–82. 2006.
EvansE, MoggsJG, HwangJR, EglyJ, WoodRD. Mechanism of open complex and dual incision formation by human nucleotide excision repair factors. EMBO J, 35:2157–2167. 1997.
17.
FerryKV, HamiltonTC, JohnsonSW. Increased nucleotide excision repair in cisplatin-resistant ovarian cancer cells. Role of ERCC1-XPF. Biochem Pharmacol, 60:1305–1313. 2000.
18.
FousteriM, MullendersLH. Transcription-coupled nucleotide excision repair in mammalian cells: Molecular mechanisms and biological effects. Cell Res, 18:73–84. 2008.
19.
HanssonJ, WoodRD. Repair synthesis by human cell extracts in DNA damaged by cis- and trans-diamminedichloroplatinum(II)Nucleic Acids Res, 17:8073–8091. 1989.
20.
HenricksenLA, UmbrichtCB, WoldMS. Recombinant replication protein A: Expression, complex formation, and functional characterization [published erratum in J Biol Chem 1994 Jun 10;269:16519]J Biol Chem, 269:11121–11132. 1994.
21.
HermansonIL, TurchiJJ. Overexpression and purification of human XPA using a Baculovirus expression system. Protein Expression Purif, 19:1–11. 2000.
22.
HessMT, SchwitterU, PetrettaM, GieseB, NaegeliH. Bipartite substrate discrimination by human nucleotide excision repair. Proc Natl Acad Sci USA, 94:6664–6669. 1997.
23.
HeyT, LippsG, KraussG. Binding of XPA and RPA to damaged DNA investigated by fluorescence anisotropy. Biochemistry, 40:2901–2910. 2001.
24.
HimmelsteinMW, BoogaardPJ, CadetJ, FarmerPB, KimJH, MartinEA, PersaudR, ShukerDE. Creating context for the use of DNA adduct data in cancer risk assessment: II. Overview of methods of identification and quantitation of DNA damage. Crit Rev Toxicol, 39:679–694. 2009.
25.
KantorG, BarsalouL, HanawaltP. Selective repair of specific chromatin domains in UV-irradiated cells from xeroderma pigmentosum complementation group C. Mutat Res, 235:171–180. 1990.
26.
KoberleB, MastersJRW, HartleyJA, WoodRD. Defective repair of cisplatin-induced DNA damage caused by reduced XPA protein in testicular germ cell tumours. Curr Biol, 9:273–276. 1999.
27.
LiC, WangLE, WeiQ. DNA repair phenotype and cancer susceptibility—A mini review. Int J Cancer, 124:999–1007. 2009.
28.
LiGM. Mechanisms and functions of DNA mismatch repair. Cell Res, 18:85–98. 2008.
29.
LiaoW, McNuttMA, ZhuWG. The comet assay: A sensitive method for detecting DNA damage in individual cells. Methods, 48:46–53. 2009.
30.
LieberMR. The mechanism of double-strand DNA breakrepair by the nonhomologous DNA end-joining pathway. Annu Rev Biochem, 79:181–211. 2010.
31.
MartinSA, LordCJ, AshworthA. DNA repair deficiency as a therapeutic target in cancer. Curr Opin Genet Dev, 18:80–86. 2008.
32.
MatakidouA, EisenT, FleischmannC, BridleH, HoulstonRS. Evaluation of xeroderma pigmentosum XPA, XPC, XPD, XPF, XPB, XPG and DDB2 genes in familial early-onset lung cancer predisposition. Int J Cancer, 119:964–967. 2006.
33.
MatsudaT, SaijoM, KuraokaI, KobayashiT, NakatsuY, NagaiA, EnjojiT, MasutaniC, SugasawaK, HanaokaF. DNA repair protein XPA binds replication protein A (RPA)J Biol Chem, 270:4152–4157. 1995.
34.
MatsunagaT, ParkCH, BesshoT, MuD, SancarA. Replication protein A confers structure-specific endonuclease activities to the XPF-ERCC1 and XPG subunits of human DNA repair excision nuclease. J Biol Chem, 271:11047–11050. 1996.
35.
ModrichP. Mismatch repair, genetic stability, and cancer. Science, 266:1959–1960. 1994.
36.
MolCD, ParikhSS, PutnamCD, LoTP, TainerJA. DNA repair mechanisms for the recognition and removal of damaged DNA bases. Annu Rev Biophys Biomol Struc, 28:101–128. 1999.
37.
MuD, SancarA. Model for XPC-independent transcription-coupled repair of pyrimidine dimers in humans. J Biol Chem, 272:7570–7573. 1997.
38.
OlaussenKA, DunantA, FouretP, BrambillaE, AndreF, HaddadV, TaranchonE, FilipitsM, PirkerR, PopperHH, StahelR, SabatierL, PignonJ, TurszT, Le ChevalierT, SoriaJ. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med, 355:983–991. 2006.
39.
OlaussenKA, MountziosG, SoriaJC. ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer. Curr Opin Pulm Med, 13:284–289. 2007.
40.
OlaussenKA, SoriaJC. Validation of ERCC1-XPF immunodetection—Letter. Cancer Res, 70:3851–3852. 2010.
41.
OlivePL. The comet assay. An overview of techniques. Methods Mol Biol, 203:179–194. 2002.
42.
PatrickSM, TurchiJJ. Replication protein A (RPA) binding to duplex cisplatin-damaged DNA is mediated through the generation of single-stranded DNA. J Biol Chem, 274:14972–14978. 1999.
43.
PatrickSM, TurchiJJ. Stopped-flow kinetic analysis of replication protein A-binding DNA. Damage recognition and affinity for single-stranded DNA reveal differential contributions of k(on) and k(off) rate constants. J Biol Chem, 276:22630–22637. 2001.
44.
PatrickSM, TurchiJJ. Xeroderma pigmentosum complementation group A protein (XPA) modulates RPA-DNA interactions via enhanced complex stability and inhibition of strand separation activity. J Biol Chem, 277:16096–16101. 2002.
45.
PayneA, ChuG. Xeroderma pigmentosum group E binding factor recognizes a broad spectrum of DNA damage. Mutat Res, 310:89–102. 1994.
46.
RobertsonAB, KlunglandA, RognesT, LeirosI. DNA repair in mammalian cells: Base excision repair: The long and short of it. Cell Mol Life Sci, 66:981–993. 2009.
47.
SarasinA, StaryA. New insights for understanding the transcription-coupled repair pathway. DNA Repair (Amst), 6:265–269. 2007.
48.
SelvakumaranM, PisarcikDA, BaoR, YeungAT, HamiltonTC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res, 63:1311–1316. 2003.
49.
SeroussiE, LaviS. Replication protein A is the major single-stranded DNA binding protein detected in mammalian cell extracts by gel retardation assays and UV cross-linking of long and short single-stranded DNA molecules. J Biol Chem, 268:7147–7154. 1993.
50.
SeveP, DumontetC. Chemoresistance in non-small cell lung cancer. Curr Med Chem Anti-Canc Agents, 5:73–88. 2005.
51.
ShilohY. ATM and related protein kinases: Safeguarding genome integrity. Nat Rev Cancer, 3:155–168. 2003.
52.
SomeyaM, SakataK, MatsumotoY, YamamotoH, MonobeM, IkedaH, AndoK, HosoiY, SuzukiN, HareyamaM. The association of DNA-dependent protein kinase activity with chromosomal instability and risk of cancer. Carcinogenesis, 27:117–122. 2006.
53.
StaresincicL, FagbemiAF, EnzlinJH, GourdinAM, WijgersN, Dunand-SauthierI, Giglia–MariG, ClarksonSG, VermeulenW, ScharerOD. Coordination of dual incision and repair synthesis in human nucleotide excision repair. EMBO J, 28:1111–1120. 2009.
54.
TakedachiA, SaijoM, TanakaK. The DDB2 complex-mediated ubiquitylation around DNA damage is oppositely regulated by XPC and Ku, and contributes to the recruitment of XPA. Mol Cell Biol, 30:2708–2723. 2010.
55.
ThompsonLH, HinzJM. Cellular and molecular consequences of defective Fanconi anemia proteins in replication-coupled DNA repair: Mechanistic insights. Mutat Res, 668:54–72. 2009.
56.
WangM, MahrenholzA, LeeSH. RPA stabilizes the XPA-damaged DNA complex through protein–protein interaction. Biochemistry, 39:6433–6439. 2000.
57.
WeissmanL, de Souza–PintoNC, StevnsnerT, BohrVA. DNA repair, mitochondria, and neurodegeneration. Neuroscience, 145:1318–1329. 2007.
58.
WoldMS. Replication protein A: A heterotrimeric, single-stranded DNA-binding protein required for eukaryotic DNA metabolism. [Review] [190 refs]Ann Rev Biochem, 66:61–92. 1997.
59.
WoodRD. DNA damage recognition during nucleotide excision repair in mammalian cells. Biochimie, 81:39–44. 1999.
60.
WoodRD, RobinsP, LindahlT. Complementation of the xeroderma pigmentosum DNA repair defect in cell-free extracts. Cell, 53:97–106. 1988.
61.
WuXM, FanW, XuSW, ZhouYK. Sensitization to the cytotoxicity of cisplatin by transfection with nucleotide excision repair gene xeroderma pigmentosun group a antisense RNA in human lung adenocarcinoma cells. Clin Cancer Res, 9:5874–5879. 2003.
